OPEN ACCESS Freely available online

Angiology: Open Access

ISSN: 2329-9495

Short Communication

Brief Note on Impact of Various Anticoagulant Therapies on Stroke Prevention in Atrial Fibrillation Patients

Bruno Grant*

Department of Cardiothoracic Surgery, Carleton University, Ottawa, Canada

DESCRIPTION

Atrial Fibrillation (AF) is a common cardiac arrhythmia characterized by irregular and often rapid heartbeats. One of the most significant complications associated with AF is an increased risk of stroke. In fact, AF is responsible for a substantial number of strokes worldwide. To mitigate this risk, anticoagulant therapies have become a basis of stroke prevention in AF patients. The choice of anticoagulant therapy plays a vital role in reducing the risk of stroke, and there are several options available, each with its own advantages and disadvantages [1].

Atrial fibrillation and stroke risk

AF disrupts the normal coordination of atrial contractions, leading to blood pooling in the atria, particularly the left atrial appendage. When blood stagnates in the heart, it is more likely to form blood clots. These clots can break loose and travel through the bloodstream, potentially causing blockages in the arteries that supply the brain. This is the primary mechanism by which AF increases the risk of stroke [2].

Several risk factors contribute to the likelihood of stroke in AF patients, including age, hypertension, diabetes, and a history of prior strokes or Transient Ischemic Attacks (TIAs). The CHA_2DS_2-VASc scoring system is commonly used to assess stroke risk in AF patients, with higher scores indicating a greater risk. The greater the risk, the more crucial anticoagulant therapy becomes in stroke prevention [3].

The impact of anticoagulant therapies on stroke prevention

Effectiveness in stroke prevention: Numerous clinical trials and real-world studies have evaluated the effectiveness of anticoagulant therapies in preventing strokes in AF patients. In general, both Vitamin K antagonists (VKAs) and Non-Vitamin K antagonist Oral Anticoagulants (NOACs) have been found to be effective in reducing stroke risk. However, NOACs have shown several advantages over VKAs in terms of efficacy, primarily by reducing the risk of intracranial bleeding.

The randomized evaluation of long-term anticoagulant therapy trial demonstrated that dabigatran, a NOAC, reduced the risk of stroke and systemic embolism when compared to warfarin. The Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (Aristotle) trial showed similar results for apixaban, while the Rivaroxaban once daily oral direct factor Xa Inhibition compared with Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation found rivaroxaban to be non-inferior to warfarin [4].

Safety profile: Safety is a crucial consideration when selecting anticoagulant therapy. The main concern with anticoagulants is the risk of bleeding. Both VKAs and NOACs carry this risk, but the severity and location of bleeding differ between the two.

VKAs have a higher risk of intracranial bleeding compared to NOACs. This is especially relevant because intracranial hemorrhage is often fatal or debilitating. NOACs are associated with a reduced risk of intracranial bleeding, making them a safer option for many patients. However, it's important to note that NOACs are not entirely free from bleeding risk, and their safety profile should be considered on an individual basis [5-6].

Monitoring and convenience: One of the major advantages of NOACs is their ease of use. Unlike warfarin, they do not require frequent INR monitoring and have fewer dietary restrictions. This convenience can lead to better adherence and, consequently, more effective stroke prevention. VKAs, on the other hand, necessitate regular INR checks to ensure patients remain within their target therapeutic range [7-8].

Reversal agents: Another critical aspect is the availability of reversal agents. Warfarin has vitamin K as a reversal agent, which can be administered in cases of bleeding or emergency surgery. In contrast, NOACs now have specific reversal agents (e.g., idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors), increasing their safety profile [9-10].

Correspondence to: Bruno Grant, Department of Cardiothoracic Surgery, Carleton University, Ottawa, Canada E-mail: grantbruno@gmail.com

Received: 05-Sep-2023, Manuscript No. AOA-23-27708; **Editor assigned:** 08-Sep-2023, PreQC No. AOA-23-27708 (PQ); **Reviewed:** 22-Sep-2023, QC No. AOA-23-27708; **Revised:** 29-Sep-2023, Manuscript No. AOA-23-27708 (R); **Published:** 06-Oct-2023, DOI: 10.35841/2329-9495.23.11.386

Citation: Grant B (2023) Brief Note on Impact of Various Anticoagulant Therapies on Stroke Prevention in Atrial Fibrillation Patients. Angiol Open Access. 11:386.

CONCLUSION

Anticoagulant therapy is an essential component of stroke prevention in atrial fibrillation patients. Both vitamin K antagonists and non-vitamin K antagonist oral anticoagulants have proven effective in reducing the risk of stroke in these individuals. However, NOACs offer certain advantages, including a more predictable pharmacokinetic profile, a lower risk of intracranial bleeding, and greater convenience, making them an increasingly popular choice.

The choice of anticoagulant therapy should be individualized, taking into consideration factors such as a patient's age, comorbidities, risk factors, and lifestyle. Furthermore, healthcare providers must consider the patient's ability to adhere to medication regimens and attend regular check-ups. Monitoring and follow-up are crucial to ensuring that anticoagulant therapy remains effective while minimizing the risk of bleeding complications. Ultimately, the decision regarding the type of anticoagulant therapy should be made in collaboration between the patient and their healthcare provider to achieve the best balance between stroke prevention and safety.

REFERENCES

1. Ylera F, Lurz R, Erdmann VA, Fürste JP. Selection of RNA aptamers to the alzheimer's disease amyloid peptide. Biochem Biophys Res Commun. 2002;290(5):1583-1588.
2. Tian Y, Wang Y, Sheng Z, Li T, Li X. A colorimetric detection method of pesticide acetamiprid by fine-tuning aptamer length. Anal Biochem. 2016;513:87-92.
3. Summers RL, Sterling SA. Emergent bleeding in patients receiving direct oral anticoagulants. Air Med J. 2016;35(3):148-155.
4. Schmitz EM, Boonen K, van Den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM, et al. Determination of dabigatran, rivaroxaban and apixaban by Ultra-Performance Liquid Chromatography-tandem Mass Spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost. 2014;12(10):1636-1646.
5. Stoltenburg R, Reinemann C, Strehlitz B. SELEX-A (r) evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng. 2007;24(4):381-403.
6. Jayasena SD. Aptamers: An emerging class of molecules that rival antibodies in diagnostics. Clini Chem. 1999;45(9):1628-1650.
7. McKeague M, DeRosa MC. Challenges and opportunities for small molecule aptamer development. J Nucleic Acids. 2012.
8. Qu H, Csordas AT, Wang J, Oh SS, Eisenstein MS, Soh HT. Rapid and label-free strategy to isolate aptamers for metal ions. ACS Nano. 2016;10(8):7558-7565.
9. Aljohani MM, Chinnappan R, Eissa S, Alsager OA, Weber K, Cialla-May D, et al. *In vitro* selection of specific dna aptamers against the anti-coagulant dabigatran etexilate. Sci Rep. 2018;8(1):13290.
10. Macaya RF, Schultze P, Smith FW, Roe JA, Feigon J. Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proc Natl Acad Sci U S A. 1993;90(8):3745-3749.